SecBot SecBot
PRESS-RELEASE ·Filed Jul 22, 2026

RGEN

Repligen Corporation
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The acquisition significantly expands Repligen's cell therapy exposure and adds a high-margin recurring revenue stream. Monitor the BioLife stockholder vote and regulatory clearance timeline, any delays or conditions could pressure the stock. Repligen's full Q2 earnings on July 28 will provide further detail on organic growth trajectory and margin expansion.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$140.09
T+0 close · Jul 22, 2026 · via day close
Latest settled
+31.47%
T+60 · $184.17
Vs SPY
+28.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $140.09entry
  2. T+1 · 4mo ago −1.78%α −0.54% · $137.60
  3. T+5 · 4mo ago +0.81%α +3.22% · $141.23
  4. T+20 · 3mo ago +25.89%α +22.99% · $176.36
  5. T+60 · 5w ago +31.47%α +28.20% · $184.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Repligen acquires BioLife Solutions for $1.5B (64% stock, 36% cash), paying $31.00/share, a 24% premium to the 90-day VWAP. The deal adds BioLife's high-margin biopreservation media franchise (CryoStor®) and expands Repligen's cell therapy exposure. Repligen also guided preliminary Q2 revenue growth of ~12% reported / 13% organic, while BioLife posted $28.5M in Q2 revenue (+21% YoY). The transaction is expected to close in Q4 2026 and be accretive to Repligen's EPS by at least $0.05 in year one and $0.25 in year two.

Key Financial Metrics

Deal Value
$1.5B

Key Facts

  • Total enterprise value of approximately $1.5 billion (64% Repligen common stock, 36% cash)
  • BioLife stockholders receive $11.25 cash + 0.1442 shares of Repligen common stock per share, total value $31.00/share
  • Implied premium of 24% to 90-day VWAP ended July 21, 2026
  • Transaction expected to close in Q4 2026, subject to regulatory approvals and BioLife stockholder approval
  • Expected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one and $0.25 in year two
  • Repligen expects at least $20M of synergies in year one and at least $30M in year two
  • Repligen preliminary Q2 2026 revenue growth of ~12% reported, ~13% organic YoY
  • BioLife preliminary Q2 2026 revenue of $28.5M, up 21% YoY from $23.4M
  • Repligen pro forma cash and cash equivalents expected to exceed $300M post-close

Financial Impact

Total enterprise value $1.5B, representing ~19.5% of Repligen's $7.7B market cap. Accretion of $0.05 EPS in year one and $0.25 in year two, with $20M-$30M in cost synergies.

revenueepsmarginsdebt

Risk Factors

  • Integration risk, combining two companies with different cultures and customer bases
  • Regulatory approval conditions or delays could push closing beyond Q4 2026
  • BioLife stockholder vote may not pass if a superior offer emerges or if shareholders deem the premium insufficient
  • Cell therapy market growth assumptions may prove optimistic, limiting expected revenue synergies
  • Dilution from stock component (64% stock), Repligen shareholders face ~19% dilution from the deal

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3331162

US Market Status

Market Closed · Opens Wed (11h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026